79 results
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1
6-K
EX-99.1
IFRX
InflaRx N.V.
21 May 24
Report of Foreign Private Issuer
4:15pm
exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Mar 24
Corporate Presentation March 2024
5:00pm
justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21
6-K
EX-99.1
IFRX
InflaRx N.V.
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1
6-K
EX-99.1
07k pa0nzqopd0
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
EX-99.1
5m4j q3ohtu
11 May 23
Current report (foreign)
8:00am
424B5
1l99clyls1gm8o6lee0
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
vjtn7tev1fz2vpcckon
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
bv3b8t087c8z
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-99.1
ldx5oo 7zud3q4og
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.1
0zvwhbkiiyp4f123414
9 Nov 22
Current report (foreign)
7:53am
6-K
EX-99.4
rffwcrcw70
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
v4a5bnid8qv1o
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
k9x040y05q43sw7wh6mj
29 Sep 22
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:00am
6-K
EX-99.1
5a7s4x0 cthe7t1
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am
6-K
EX-99.3
tr3fjjx eaf4
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
yxq5bcmw094iefqw98
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
gkj13i
26 Jul 22
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:35am
6-K
EX-99.1
zlgfhvw9owejk49c3n
6 Jul 22
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
8:30am